Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 10/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1544664 | 1.00 | EGFR (0.52) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL19957454 | 0.88 | EGFR (0.44) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL15743609 | 0.84 | EGFR (0.46) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL30457508 | 0.84 | EGFR (0.46) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL28650514 | 0.83 | EGFR (0.44) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL24150785 | 0.82 | NR4A2 (0.47) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL1545433 | 0.82 | EGFR (0.46) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL1817600 | 0.81 | EGFR (0.45) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL30629495 | 0.80 | EGFR (0.44) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL22125645 | 0.79 | EGFR (0.44) | EGFRIDO1TDO2LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622970-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025064853-A1 | RIPK3 INHIBITORS AND METHODS OF USE | Momentum Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-4433485-A1 | ADENOSINE RECEPTOR ANTAGONISTS | Crossignal Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024112854-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-4251617-A1 | (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023091604-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022112491-A1 | (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |